Dr Reddys Laboratories Ltd.
BSE: 500124 | Sector: Health care |
NSE: DRREDDY | ISIN Code: INE089A01023 |
BSE 14:56 | 30 Jan | 4308.90 |
-9.40 (-0.22%) |
OPEN
4315.00 |
HIGH
4338.25 |
LOW
4281.35 |
NSE 14:44 | 30 Jan | 4302.70 |
-11.30 (-0.26%) |
OPEN
4319.95 |
HIGH
4339.45 |
LOW
4284.95 |
OPEN | 4315.00 |
PREVIOUS CLOSE | 4318.30 |
VOLUME | 17232 |
52-Week high | 4645.55 |
52-Week low | 3655.00 |
P/E | 30.40 |
Mkt Cap.(Rs cr) | 71,752 |
Buy Price | 4306.55 |
Buy Qty | 7.00 |
Sell Price | 4309.55 |
Sell Qty | 1.00 |
About Dr Reddys Laboratories Ltd.
Dr Reddy's Laboratories Ltd (DRL) is an integrated global pharmaceutical company committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &Active Ingredients Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs) custom pharmac...> More
Dr Reddys Laboratories Ltd - Key Fundamentals
Parameter | Values | ||
Market Cap | ( cr) | 71,752 | |
EPS - TTM | () | [*S] | 141.73 |
P/E Ratio | (X) | [*S] | 30.40 |
Face Value | () | 5 | |
Latest Dividend | (%) | 600.00 | |
Latest Dividend Date | 11 Jul 2022 | ||
Dividend Yield | (%) | 0.69 | |
Book Value / Share | () | [*S] | 1156.24 |
P/B Ratio | () | [*S] | 3.73 |
News
-
DRL posts strong 77% profit growth to Rs 1,247 cr riding on US, Russia
-
RIL, Dr Reddy's Labs: 5 Nifty500 stocks cross 200-DMA, defying weak trend
-
Strong US pipeline, sustained growth trajectory main trigger for Dr Reddy's
-
Stocks to Watch: NDTV, Dr.Reddy's, IndiGo, SBI, Zee, Consumer Firms
-
Adani Green could replace Dr Reddy's in Sensex during December review
Announcement
-
Dr. Reddy's Laboratories Limited - Analysts/Institutional Investor Meet/Con. Call Updates
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Form 6-K For The Quarter Ended December 31 2022 Filed With United States Securities And Exchange Com
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
-
Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2022
Dr Reddys Laboratories Ltd - Financial Results
Particulars ( cr) | Dec 2022 | Dec 2021 | % Chg |
Net Sales | 6789.9 | 5338.3 | 27.19 |
Other Income | 64.6 | 74.3 | -13.06 |
Total Income | 6854.5 | 5412.6 | 26.64 |
Total Expenses | 4851.3 | 4122.6 | 17.68 |
Operating Profit | 2003.2 | 1290 | 55.29 |
Net Profit | 1243.9 | 709.3 | 75.37 |
Equity Capital | 83.3 | 83.2 | - |
Dr Reddys Laboratories Ltd - Peer Group
Company | Price() | Chg (%) | Mkt Cap ( CR) |
Sun Pharma.Inds. | 1046.75 | 0.30 | 251146.72 |
Divi's Lab. | 3365.20 | -0.60 | 89329.23 |
Cipla | 1033.40 | -1.30 | 83410.88 |
Dr Reddy's Labs | 4308.90 | -0.22 | 71751.80 |
Torrent Pharma. | 1544.10 | 0.41 | 52258.52 |
Abbott India | 20985.15 | -1.11 | 44593.44 |
Zydus Lifesci. | 427.40 | -0.66 | 43261.43 |
Dr Reddys Laboratories Ltd - SHAREHOLDING PATTERN
|
|
Dr Reddys Laboratories Ltd - Research Reports
Date | Broker | Action | Price | Report |
29/11/2022 | Nirmal Bang | Accumulate | 4407 | Details |
01/11/2022 | Nirmal Bang | Accumulate | 4461 | Details |
07/06/2022 | Nirmal Bang | Buy | 4334 | Details |
28/07/2021 | Motilal Oswal | Neutral | 4688 | Details |
18/05/2021 | Nirmal Bang | Accumulate | 5197 | Details |
Dr Reddys Laboratories Ltd - RETURNS
Period | BSE | NSE | Sensex | NIFTY |
1 Week | -0.69% | -0.81% | -2.76% | -3.09% |
1 Month | 1.76% | 1.54% | -2.60% | -3.02% |
3 Month | -3.41% | -3.53% | -1.17% | -1.29% |
6 Month | 5.34% | 5.19% | 2.93% | 2.33% |
1 Year | 2.16% | 1.99% | 3.60% | 2.67% |
3 Year | 36.60% | 36.38% | 44.84% | 45.88% |
Dr Reddys Laboratories Ltd - STOCK STRENGTH
Today's Low/High | 4281.35 | 4338.25 | |
Week Low/High | 4176.85 | 4382.00 | |
Month Low/High | 4176.85 | 4400.00 | |
YEAR Low/High | 3655.00 | 4646.00 | |
All TIME Low/High | 3.83 | 5614.00 |
Quick Links for Dr Reddys Laboratories:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices